A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 192,099 shares of ARQT stock, worth $2.75 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
192,099
Holding current value
$2.75 Million
% of portfolio
0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$8.32 - $11.0 $1.6 Million - $2.11 Million
192,099 New
192,099 $1.79 Million
Q4 2023

Feb 13, 2024

BUY
$1.84 - $4.82 $726,984 - $1.9 Million
395,100 New
395,100 $1.28 Million
Q3 2022

Nov 14, 2022

BUY
$17.85 - $26.95 $967,470 - $1.46 Million
54,200 Added 501.85%
65,000 $1.24 Million
Q2 2022

Aug 12, 2022

BUY
$16.33 - $22.2 $176,363 - $239,760
10,800 New
10,800 $230,000
Q3 2020

Nov 13, 2020

SELL
$23.44 - $32.28 $649,288 - $894,156
-27,700 Closed
0 $0
Q2 2020

Aug 13, 2020

BUY
$24.48 - $36.56 $678,096 - $1.01 Million
27,700 New
27,700 $838,000

Others Institutions Holding ARQT

About Arcutis Biotherapeutics, Inc.


  • Ticker ARQT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 60,187,500
  • Market Cap $861M
  • Description
  • Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...
More about ARQT
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.